Amalgamated Financial’s Evelo Biosciences, Inc. Common Stock EVLO Stock Holding History

Amalgamated Financial’s Portfolio EVLO Stock Details EVLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$17K	Buy	+247	New	+$20.6K	﹤0.01%	2794

Other funds holding EVLO

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SOMRS

State of Michigan Retirement System Lansing, Michigan $22.6B AUM 40.24% 1-Year Est. Return

Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Amalgamated Financial's EVLO Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Evelo Biosciences, Inc. Common Stock (EVLO) in Q1 2022: 247 shares worth $17K. The stake represents ﹤0.01% of the portfolio and ranks #2794 among its holdings.

68 funds tracked by Wall St. Rank hold EVLO as of Q1 2022.

Amalgamated Financial held 247 shares of Evelo Biosciences, Inc. Common Stock worth $17K as of Q1 2022.
Evelo Biosciences, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Evelo Biosciences, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2794 holding.
68 funds tracked by Wall St. Rank held Evelo Biosciences, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.